Does a fixed dose of dabigatran provide similar efficacy and safety compared to warfarin in the treatment of acute venous thromboembolism?
A fixed dose of dabigatran is as effective and safe as warfarin for treating acute venous thromboembolism, with the added benefit of not requiring laboratory monitoring.
For the treatment of acute venous thromboembolism, a fixed dose of dabigatran is as effective as warfarin, has a safety profile that is similar to that of warfarin, and does not require laboratory monitoring. (ClinicalTrials.gov number, NCT00291330.)
Schulman et al. (Sun,) studied this question.